Cancer screening cadence

For two generations the framing was simple: more screening, earlier, for everyone, saves lives. The 2022–2026 evidence has not overturned that picture so much as compressed it. A few modalities — biennial mammography from 40, colonoscopy or FIT from 45, primary HPV from 30, low-dose CT in heavy ever-smokers, one-time HCV and AAA screens in defined groups — sit on robust mortality data. The rest carry net benefit only in narrow risk strata, and a handful of routine tests now have a documented overdiagnosis problem that rivals or exceeds their mortality benefit. The largest randomized cancer-screening meta-analysis of the modern era found that across six common modalities, mean life-extension is measured in days, not years. That is the calibration this article is built around.

The first reframe: disease-specific vs all-cause mortality

A screening test can prevent death from cancer X without measurably extending the average life of the screened population. The 2023 JAMA Internal Medicine meta-analysis of 18 randomized trials in 2.1 million participants quantified exactly how compressed that gain is when averaged across everyone screened, including those who never had the disease and those who avoid cancer death only to die of something else.^[1]

These are means, and a mean of zero is compatible with substantial individual benefit — the woman whose Stage I tumor was caught at mammography gains years; the millions of women who never develop breast cancer gain none. But the population frame is the one the policy decision sits on, and it argues for a small number of high-value tests done well, not a long list done because they exist.

A reasonable counter-fear — that screening kills patients indirectly, through false-positive cascades, radiation, or unnecessary procedures — was tested in a 2025 JAMA Network Open meta-analysis of 17 RCTs in 1.3 million participants. Off-target mortality rose by 0.2%, statistically indistinguishable from zero.^[2] Screening doesn't passively harm. It just earns less than its marketing implies.

Colorectal — start at 45, complete what you start (Strong)

The USPSTF lowered the colorectal cancer screening initiation age from 50 to 45 in May 2021, prompted by a ~2%/year rise in early-onset CRC incidence among under-50s. Grade B from 45 to 49; Grade A from 50 to 75; individualized 76–85.^[3] Adoption was rapid — by 2023 ordering rates in the 45–49 cohort had effectively normalized to those of the 50+ cohort in commercially insured populations.

The interesting evidence is NordICC, the first large RCT of screening colonoscopy itself, randomizing 84,585 healthy 55–64-year-olds in Poland, Norway, Sweden, and the Netherlands.^[4] After 10 years, the intention-to-screen analysis showed CRC incidence of 0.98% in the invitation arm vs 1.20% in usual care — an 18% relative reduction. CRC-specific mortality was 0.28% vs 0.31%, not statistically significant.

The signal-to-noise problem was adherence: only 42% of those invited actually showed up for the colonoscopy. A per-protocol model assuming 100% adherence reconstructs a 31% incidence reduction and 50% mortality reduction. The honest reading is that colonoscopy works when it happens, and the headline harm of the trial is the dropout rate. A 2024 reanalysis of all-cause mortality found no signal at all on absolute lifespan even under the perfect-adherence model — the disease-specific gain gets absorbed by competing mortality in the 55–75 window.

What this means in practice. Start at 45. Use the modality you will actually complete. Annual fecal immunochemical test (FIT) at scale delivers comparable mortality reduction to 10-yearly colonoscopy in modeling — and modeling assumes you do it. Adherence is the variable that actually moves the outcome.

Breast — biennial from 40, with one open question (Strong)

The USPSTF moved the initiation age for screening mammography from 50 to 40 in April 2024, Grade B for biennial screening through age 74.^[5] The driver was a 2%/year rise in invasive breast cancer incidence in the 40–49 cohort between 2015 and 2019, plus modeling that initiating at 40 averts an additional ~1.3 breast cancer deaths per 1,000 women screened over a lifetime — and roughly 10.7 deaths per 1,000 in non-Hispanic Black women, whose mortality rate is 40% higher.

Two clinical scenarios still carry an "I" statement — insufficient evidence rather than affirmative recommendation:

• Screening beyond age 75. No trial data; competing mortality starts to dominate.
• Supplemental ultrasound or MRI for dense breasts (~40% of screened women). MRI undeniably finds more tumors. No RCT has yet shown that detection translates into fewer breast cancer deaths.

The DCIS overdiagnosis problem

Ductal carcinoma in situ — "Stage 0" — accounts for about 18% of newly diagnosed breast cancers in the US, almost all of it detected only because of screening. Modeling estimates that ~1 in 5 detected DCIS cases in women 50–75 is overdiagnosis.^[6] An 8-year prospective series of 1,780 women who declined upfront surgery showed only 8–14% progression to invasive cancer, sharply below the 20–50% lifetime models that justified routine lumpectomy plus radiation plus endocrine therapy. The COMET active-surveillance trial is now testing whether the standard aggressive treatment of low-risk DCIS is itself the harm.

The site's overall framing applies: screening doesn't cause cancer, but it does manufacture cancer diagnoses, and that distinction matters for what you do with a "Stage 0" result.

Cervical — primary HPV, every five years (Strong)

Primary high-risk HPV testing detects 40% more high-grade lesions (CIN3+) and 30% more cervical cancers per screening round than liquid-based cytology, and the adjusted odds of subsequent CIN3+ after a negative HPV test is 0.14 — about a seven-fold lower forward risk.^[7] On that basis the UK, the Netherlands, and the European Commission's screening guidance extend the interval to 5 years for HPV-negative women (longer in some models for women 40+).^[8]

The behavioral catch is that women habituated to a 3-year cytology cadence often experience the longer interval as undertreatment. The biology argues the other way — persistent HPV infection takes years to progress through cellular dysplasia to invasive cancer, and a negative HPV test has a very high forward negative predictive value. Patient education is the actual implementation problem; the science isn't.

Prostate — risk-stratified PSA, not population PSA (Moderate)

The two-decade transatlantic argument between ERSPC (mortality benefit) and PLCO (no benefit) has largely been resolved by recognizing that PLCO's control arm was massively contaminated by opportunistic PSA testing outside the trial.^[9] Adjusting for mean lead time makes the two trials roughly compatible, with PSA screening conferring a 7–9% reduction in prostate cancer death per year of lead time.

At 23 years of follow-up across 162,236 men, ERSPC shows a 13% relative reduction in prostate cancer mortality (RR 0.87, 95% CI 0.80–0.95).^[10] The absolute risk reduction is 0.22%. To prevent one prostate cancer death, 456 men must be invited to screen and 12 must be diagnosed and treated.

The implication is not "PSA doesn't work." It is that untargeted PSA testing on every adult man generates a large overdiagnosis and overtreatment cost — incontinence, erectile dysfunction, the cardiovascular morbidity of androgen deprivation — for a small absolute mortality gain. Modern urological guidelines and several European national programs are converging on a stratified pathway: baseline PSA, longer intervals for low values, multiparametric MRI before any biopsy, and active surveillance for Gleason 6 disease. Discuss the test; don't reflexively order it.

Lung — low-dose CT in actual heavy smokers (Strong)

The USPSTF 2021 update broadened low-dose CT eligibility to adults 50–80 with a ≥20 pack-year history who currently smoke or quit within 15 years.^[11] Stop screening once a person has been off cigarettes for 15 years or develops a comorbidity that would rule out curative resection.

LDCT works because it catches small, resectable nodules years before symptoms. False positives are common (benign granulomas and hamartomas light up the same way), and serial surveillance scans, bronchoscopy, and needle biopsy of benign tissue are part of the cost — which is why the eligibility criteria are tight. Screening is highly cost-effective in the target population and not justified outside it.

Skin — not routinely (Insufficient evidence)

The USPSTF gives an "I" statement to routine clinician-performed visual skin checks in asymptomatic adults.^[12] A pooled review of 20 studies in over 6 million patients found no population-level melanoma mortality benefit. Routine screening finds a great deal of Stage 0 / Stage I melanoma — much of which appears to be indolent — without proportionally reducing late-stage, lethal nodular melanoma, which often progresses rapidly between screening intervals (length-time bias).

This isn't an argument against dermatologic care for visible suspicious lesions or for patients with high-risk family history, fair Fitzpatrick types, or atypical-mole syndromes. It is an argument against the routine annual "skin check" as a population-wide longevity lever.

Hepatitis C and AAA — one-time, defined-population screens (Strong)

Two screening tests deliver outsized benefit relative to their effort because they are one-time, well-targeted, and curative or definitively actionable downstream.

• Hepatitis C, one-time, all adults 18–79. With direct-acting antivirals achieving cure rates well above 95%, the case for universal one-time HCV antibody screening (reflex to RNA PCR if positive) is now overwhelming; the USPSTF dropped the prior birth-cohort and risk-based framing in 2020.^[13] Hepatitis B remains risk-stratified.
• Abdominal aortic aneurysm — one-time ultrasound, men 65–75 who have ever smoked. The USPSTF criterion is narrow because that is where the survival benefit concentrates. The 2024 European Society for Vascular Surgery guidelines emphasize the same point: defer CT angiography and surgical planning until the operative threshold (~55 mm in men, ~50 mm in women) is met, and route patients to volume-adequate centers (15+ open, 15+ endovascular repairs annually).^[14]

The overdiagnosis problem — visible most in thyroid (Caution)

Overdiagnosis isn't a screening failure mode; it's a screening byproduct. The clearest illustration is thyroid cancer: global incidence has surged for three decades while mortality has stayed flat. Modeling using the Papillary Thyroid Carcinoma Microsimulation framework estimates that 72% to 94% of all US papillary thyroid cancer diagnoses between 1991 and 2019 were overdiagnoses — clinically silent micropapillary lesions that would never have surfaced symptomatically.^[15] Several hundred thousand people received total thyroidectomy, radioactive iodine, and lifelong levothyroxine for a "cancer" that didn't behave like one. See Thyroid management for the active-surveillance reframe that the 2025 American Thyroid Association guidelines have now formally adopted.

The defensive principle is to screen only where evidence supports the cadence, take overdiagnosis seriously when deciding what to do with an early-stage result, and prefer active surveillance over reflex resection when the evidence supports it (DCIS, low-grade prostate, sub-centimeter thyroid nodules).

Multi-cancer early detection (MCED) — promising, not ready (Weak / preliminary)

The biggest unsolved problem in cancer screening is that ~87% of cancer deaths come from cancers without any guideline-recommended screening modality. Multi-cancer early detection assays — circulating cell-free DNA methylation panels, of which Galleri is the most prominent — promise to find dozens of cancers from a single blood draw.^[16]

The first large interventional readout is the NHS-Galleri trial in over 142,000 asymptomatic 50–77-year-olds.^[17] The headlines are mixed:

• Primary endpoint missed: no statistically significant reduction in combined Stage III/IV cancer incidence in the intervention arm.
• Stage shift in the right direction: substantial absolute increase in Stage I/II detection across 12 typically late-presenting cancers, and a ~4× higher overall detection rate when added to standard screening.
• Reduction in emergency-presentation diagnoses — meaningful for both prognosis and acute healthcare cost.
• Adherence reassurance: women with negative Galleri results maintained >80% adherence to standard mammography, against the worry that a negative blood test would seed false confidence.

The cautious read is that MCED tests find earlier-stage cancers without yet showing they prevent late-stage cancers — a pattern entirely compatible with detecting indolent disease faster rather than aggressive disease earlier. ASCO, CAP, ESMO, and the USPSTF currently agree: insufficient evidence to recommend MCED for routine population screening outside clinical trials.^[18] That position will likely move once a randomized trial shows a hard mortality endpoint. It hasn't yet.

Practical guidance

1. Run the evidence-backed cadence and complete it. Colorectal from 45 (colonoscopy or annual FIT — the one you'll actually do). Mammography biennially from 40 to 74. Primary HPV every 5 years 30–65. Low-dose CT annually if you meet the 50–80 / 20+ pack-year / ≤15 years quit criteria. One-time HCV antibody if you've never been tested. One-time AAA ultrasound for men 65–75 with any smoking history.
2. Have the PSA conversation; don't reflex-order it. Shared decision around age 50 (45 with family history or African ancestry); use baseline-stratified intervals and demand multiparametric MRI before any biopsy if you do screen.
3. Take overdiagnosis seriously when you get a result. A Stage 0 finding (DCIS, ≤1 cm thyroid nodule, Gleason 6 prostate) doesn't automatically mean immediate surgery — active surveillance is now standard-of-care in defined low-risk subsets.
4. Don't add tests that lack evidence. Routine whole-body skin checks, opportunistic neck ultrasound, full-body MRI marketed to healthy adults, and MCED panels outside trials all currently sit closer to harm than benefit on the population evidence.
5. Recognize that screening reduces cancer mortality, not necessarily all-cause mortality. The mean life-extension in the trial data is small. The behavioral levers — not smoking, blood pressure, lipids, sleep, exercise, weight — still dominate the longevity arithmetic.

What's overrated

• Whole-body MRI and CT for healthy adults. Marketed aggressively; no RCT evidence of mortality benefit; substantial false-positive cascade.
• Routine annual dermatologic skin checks in average-risk asymptomatic adults — the population data show stage shift without lethal-melanoma mortality reduction.
• Opportunistic neck ultrasound for nonpalpable thyroid nodules — the modality that produced an iatrogenic cancer epidemic.
• MCED tests as currently sold — biologically impressive, not yet shown to reduce the cancers people actually die of.

Further reading

• Bretthauer M et al. Estimated Lifetime Gained With Cancer Screening Tests: A Meta-Analysis of Randomized Clinical Trials. JAMA Intern Med 2023.^[19]
• Bretthauer M et al. Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death (NordICC). NEJM 2022.^[20]
• US Preventive Services Task Force. Screening for Breast Cancer: USPSTF Recommendation Statement. JAMA 2024.^[21]
• Rebolj M et al. Primary cervical screening with high risk human papillomavirus testing: observational study. BMJ 2019.^[22]
• Hugosson J et al. Mortality results from the ERSPC at 23 years of follow-up. 2025.^[23]
• Henrikson NB et al. Skin Cancer Screening: Updated Evidence Report and Systematic Review for the USPSTF. JAMA 2023.^[24]
• Lortet-Tieulent J et al. Overdiagnosis of Papillary Thyroid Cancer in the United States, 1991–2019. 2024.^[25]
• NHS-Galleri trial — topline results. GRAIL 2026.^[26]

---